Search results
Showing 1401 to 1450 of 2065 results for work
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)
Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.
Evidence-based recommendations on capivasertib (Truqap) with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment in adults.
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.
Cladribine for treating relapsing–remitting multiple sclerosis (TA616)
Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis in adults.
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.
Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued Reference number: GID-TAG411
In development Reference number: GID-TA11345 Expected publication date: TBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726
In development Reference number: GID-TA11015 Expected publication date: TBC
In development Reference number: GID-TA11014 Expected publication date: TBC
Discontinued Reference number: GID-IP267
Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.
In development Reference number: GID-TA11277 Expected publication date: TBC
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
Discontinued Reference number: GID-TAG416
In development Reference number: GID-TA11679 Expected publication date: TBC
Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Discontinued Reference number: GID-TA10377
In development Reference number: GID-TAG406 Expected publication date: TBC
In development Reference number: GID-TA10483 Expected publication date: TBC
Extra corporeal membrane oxygenation for acute heart failure in children
Discontinued Reference number: GID-IP1153
Discontinued Reference number: GID-TAG390
Intensity modulated radiotherapy for head and neck cancer [ID15]
Discontinued Reference number: GID-TAG397
Discontinued Reference number: GID-TAG396
Discontinued Reference number: GID-CGWAVE0773
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]
In development Reference number: GID-TA11629 Expected publication date: TBC
In development Reference number: GID-TA11310 Expected publication date: TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099
In development Reference number: GID-TA11640 Expected publication date: TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development Reference number: GID-TA10900 Expected publication date: TBC
In development Reference number: GID-TAG380 Expected publication date: TBC
Multiple sclerosis (primary-progressive) - fingolimod [ID62]
Discontinued Reference number: GID-TAG221
Discontinued Reference number: GID-TAG244
In development Reference number: GID-TA10577 Expected publication date: 21 April 2021
In development Reference number: GID-TA11482 Expected publication date: TBC
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)
Evidence-based recommendations on cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for treating late-onset Pompe disease in adults.
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia in remission with minimal residual disease activity in adults.
Evidence-based recommendations on brentuximab vedotin (Adcetris) for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.
Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.
View recommendations for IPG769Show all sections
Bevacizumab for untreated malignant pleural mesothelioma [ID1183]
Discontinued Reference number: GID-TA10197
Evidence-based recommendations on rucaparib (Rubraca) for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Discontinued Reference number: GID-TAG377
In development Reference number: GID-TA11269 Expected publication date: TBC
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
Belatacept for the prevention of organ rejection in kidney transplantation [ID87]
Discontinued Reference number: GID-TAG239
decision that is right for you. This decision aid is designed for you to work through with your healthcare professional. You might also...
decision that is right for you. This decision aid is designed for you to work through with your healthcare professional. You might also...